The general trend in cancer research innovation over the last 50 years has been from the use of crude tools, such as chemotherapy, radiation and surgery to more nuanced and fine-tuned tools, such as the use of antibodies to deliver cytotoxins only to the site of malignant tissue. This new class of cancer treatment is widely referred to as precision medicine, and it promises to radically transform the ways in which cancer is treated and improve outcomes for many types of cancer that have so far proven to be resistant to effective treatment and more information click here.

One company that is seeking to create the next generation of precision cancer treatment is Tempus. Co-founded by internet entrepreneur and famous medical philanthropist Eric Lefkofsky, Tempus seeks to harness the power of the human genome and other vast sources of data to create actionable intelligence for physicians, oncologists and medical researchers that will enable them to custom-tailor treatment regimens to individual patients, to an extent never before imagined and learn more about Eric.

One example of the application of such nuanced approaches to cancer treatment is the ability of oncologists possessing large scale data and advanced analytics to determine why it is that certain subgroups of patients respond better to a given chemotherapeutic regimes than another subgroup of patients. These problems arise very frequently in the treatment of cancer. And they offer the potential to radically increase the survivability of many types of cancer, giving physicians a deeper understanding of why certain drugs and other treatments are effective for some patients and why they may not be in others. When combined with the vast new quantities of data provided by cheap human genomic sequencing, this promises to blow the ceiling completely off of the prior limits of cancer treatment, leading to the disease someday becoming a chronic illness along the line of AIDS or hepatitis, with which people can live for decades on end and Eric’s lacrosse camp.

Through the creation of Tempus, Lefkofsky is helping to bring this new paradigm of 21st century medicine to fruition. He predicts that within the next ten years, many subtypes of cancer will become less fatal illnesses and more chronic nuisances that patients can learn to live with.

More Visit: http://www.lightbank.com/team/eric-lefkofsky